Article
Scalable Production of a <i>De Novo</i> SARS-CoV-2 Antiviral miniprotein in E <i>scherichia coli</i>
2026-06-24
Abstract excerpt
The rapid emergence of SARS-CoV-2 variants that evade neutralizing antibodies underscores the need for next-generation antiviral biologics that combine molecular precision with scalable, cost-effective manufacturing. Computationally designed miniproteins targeting the receptor-binding domain (RBD) of the spike protein offer a compelling alternative to monoclonal antibodies due to their small size, high thermal sta...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 69ef8508-3319-502c-a79e-7bf1c7cc31d9
- DOI
- 10.64898/2026.06.23.734092
